 <h1>Testosterone Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2>In Summary</h2><p><b>More frequently reported side effects include:</b> deep vein thrombosis.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to testosterone: buccal patch extended release</i></p><p>Other dosage forms:</p><ul><li>implant, oil, solution</li><li>nasal gel/jelly</li><li>transdermal patch extended release</li></ul><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, testosterone may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking testosterone:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Pain, redness, or swelling in the arm or leg</li>
<li>trouble breathing</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking testosterone:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Blurred vision</li>
<li>headache</li>
<li>seizures</li>
<li>slurred speech</li>
<li>sudden and severe inability to speak</li>
<li>temporary blindness</li>
<li>weakness in the arm or leg on one side of the body, sudden and severe</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of testosterone may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Gum or mouth irritation</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bad, unusual, or unpleasant (after) taste</li>
<li>bleeding gums</li>
<li>blemishes on the skin</li>
<li>breast pain</li>
<li>change in taste</li>
<li>cough</li>
<li>crying</li>
<li>depersonalization</li>
<li>diarrhea</li>
<li>discouragement</li>
<li>dizziness</li>
<li>dry mouth</li>
<li>dysphoria</li>
<li>enlarged breasts</li>
<li>euphoria</li>
<li>fear or nervousness</li>
<li>feeling sad or empty</li>
<li>gum pain or blisters</li>
<li>hoarseness</li>
<li>indigestion</li>
<li>irritability</li>
<li>itching skin</li>
<li>loss of appetite</li>
<li>loss of interest or pleasure</li>
<li>lower back or side pain</li>
<li>mouth ulcers</li>
<li>nausea</li>
<li>noisy breathing</li>
<li>painful or difficult urination</li>
<li>paranoia</li>
<li>passing of gas</li>
<li>pounding in the ears</li>
<li>quick to react or overreact emotionally</li>
<li>rapidly changing moods</li>
<li>redness and swelling of the gums</li>
<li>slow or fast heartbeat</li>
<li>stinging of the lips</li>
<li>stomach cramps, pain, fullness, or discomfort</li>
<li>swelling of the gums</li>
<li>swelling of the nose</li>
<li>tiredness</li>
<li>toothache</li>
<li>trouble concentrating</li>
<li>trouble sleeping</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><p>
<div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to testosterone: buccal film extended release, compounding powder, intramuscular solution, nasal gel, oral capsule, subcutaneous implant, subcutaneous solution, transdermal cream, transdermal film extended release, transdermal gel, transdermal ointment, transdermal solution</i></p><h3>General</h3><p>The most frequently reported side effects with this drug are edema, acne, site pain, injection site erythema, cough or dyspnea during or immediately after injection.</p>
<p></p>
<p>The most frequently reported side effects with testosterone topical are skin reaction (16.1%) and allergic contact dermatitis (up to 37%).<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Testosterone topical: Skin reaction (16.1%), burn-like blisters (12%), itching, allergic contact dermatitis (up to 37%)</p>
<p><b>Common</b> (1% to 10%): Acne, induration, burning</p>
<p><b>Uncommon</b> (0.1% to 1%): Alopecia, erythema, rash (including rash popular), pruritus, dry skin, folliculitis (testosterone topical)</p>
<p><b>Frequency not reported</b>: Seborrhea, urticaria, male pattern baldness, hirsutism injection site inflammation</p>
<p><b>Postmarketing reports</b>: Angioedema, angioneurotic edema, hyperhidrosis, discolored hair, leukocytoclastic vasculitis<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Very common</b> (10% or more): Accelerated growth</p>
<p><b>Common</b> (1% to 10%): Increased estradiol, hypogonadism</p>
<p><b>Uncommon</b> (0.1% to 1%): Increased blood testosterone</p>
<p><b>Frequency not reported</b>: Signs of virilization in women (e.g., hoarseness, acne, hirsutism, menstrual irregularity, clitoral enlargement, and alopecia), precocious puberty (in prepubertal males)</p>
<p><b>Postmarketing reports</b>: Hyperparathyroidism, prolactin increased, testosterone increased<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Testosterone buccal film: Gingivitis (32.6%)</p>
<p><b>Common</b> (1% to 10%): Diarrhea, oily stools (due to IM injection oily solvent); Testosterone topical: Gastroesophageal reflux disease, gastrointestinal bleeding, gum or mouth irritation (9.2%), taste bitter, gum pain, gum tenderness, gum edema, taste perversion</p>
<p><b>Uncommon</b> (0.1% to 1%): Nausea</p>
<p><b>Rare</b> (less than 0.1%): Abdominal pain</p>
<p><b>Frequency not reported</b>: Abdominal disorder, intraabdominal hemorrhage</p>
<p><b>Postmarketing reports</b>: Vomiting; Testosterone buccal film: Dry mouth, gingival swelling, lip swelling, mouth ulceration, stomatitis<sup>[Ref]</sup></p><p>The majority of gum-related adverse events were transient.<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Testosterone topical: Application site pruritus (up to 37%), application site blistering (12%)</p>
<p><b>Common</b> (1% to 10%): Injection site pain, injection site discomfort, injection site pruritus, erythema, injection site hematoma, injection site irritation, injection site inflammation; injection site reaction; Topical testosterone: Application site erythema, application site warmth, application site irritation, application site vesicles, application site exfoliation, application site burning, application site induration, bullae at application site, mechanical irritation at application site, rash at application site, contamination of application site</p>
<p><b>Postmarketing reports</b>: Injection site abscess, procedural pain, application site swelling (topical testosterone)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hot flush, hypertension</p>
<p><b>Uncommon</b> (0.1% to 1%): Cardiovascular disorder</p>
<p><b>Frequency not reported</b>: Venous thromboembolism</p>
<p><b>Postmarketing reports</b>: Angina pectoris, cardiac arrest, cardiac failure, coronary artery disease, coronary artery occlusion, myocardial infarction, tachycardia, cerebral infarction, cerebrovascular accident, circulatory collapse, deep venous thrombosis, syncope, thromboembolism, thrombosis, venous insufficiency, stroke<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Abnormal prostate examination, benign prostate hyperplasia (BPH), ejaculation disorder, prostatitis</p>
<p><b>Uncommon</b> (0.1% to 1%): Prostate induration, prostatic disorder, testicular pain, decreased urine flow, urinary retention, urinary tract disorder, nocturia, dysuria</p>
<p><b>Rare</b> (less than 0.1%): Micturition disorders, epididymitis, bladder irritability, impotence, inhibition of testicular function and testicular atrophy</p>
<p><b>Frequency not reported</b>: Oligospermia, priapism, benign prostatic hyperplasia (prostatic growth to eugonadal state), excessive frequency and duration of erections; Pediatrics: Precocious sexual development, an increased frequency of erections, phallic enlargement</p>
<p><b>Postmarketing reports</b>: Prostate infection, calculus urinary, dysuria, hematuria, urinary tract disorder, pollakiuria, azoospermia<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Polycythemia, hematocrit increased</p>
<p><b>Uncommon</b> (0.1% to 1%): Increased red blood cell count, increased hemoglobin, prolonged activated partial thromboplastin time, prolonged prothrombin time</p>
<p><b>Frequency not reported</b>: Blood and lymphatic system disorders, suppression of clotting factors II, V, VII, and X, bleeding in patients on concomitant anticoagulant therapy</p>
<p><b>Postmarketing reports</b>: Thrombocytopenia, anemia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Weight increased, appetite increased, fluid retention (sodium, chloride, water, potassium, calcium, and inorganic phosphates)</p>
<p><b>Uncommon</b> (0.1% to 1%): Increased glycosylated hemoglobin, hypercholesterolemia, increased triglyceride</p>
<p><b>Frequency not reported</b>: Abnormal lipids (decrease in serum LDL, HDL, and triglycerides), metabolism and nutrition disorders, hypercalcemia</p>
<p><b>Postmarketing reports</b>: Hypoglycemia, diabetes mellitus, fluid retention, hyperlipidemia, hypertriglyceridemia, blood glucose increased<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, hemarthrosis (testosterone topical)</p>
<p><b>Uncommon</b> (0.1% to 1%): Arthralgia, pain in extremity, muscle spasm, muscle strain, myalgia, musculoskeletal stiffness, increased creatine phosphokinase</p>
<p><b>Frequency not reported</b>: Pediatrics: Premature epiphyseal closure, increased bone formation</p>
<p><b>Postmarketing reports</b>: Musculoskeletal chest pain, musculoskeletal pain, myalgia, osteopenia, osteoporosis, systemic lupus erythematosus<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, vertigo (topical testosterone)</p>
<p><b>Uncommon</b> (0.1% to 1%): Migraine, tremor, dizziness</p>
<p><b>Frequency not reported</b>: Nervousness, paresthesia</p>
<p><b>Postmarketing reports</b>: Cerebrovascular insufficiency, reversible ischemic neurological deficiency, transient ischemic attack, amnesia<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Prostatic specific antigen (PSA) increased, prostate cancer</p>
<p><b>Uncommon</b> (0.1% to 1%): Prostatic intraepithelial neoplasia</p>
<p><b>Rare</b> (less than 0.1%): Neoplasms benign, malignant, and unspecified (including cysts and polyps)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue, hyperhidrosis; chills, body pain, smell disorder</p>
<p><b>Uncommon</b> (0.1% to 1%): Breast induration, breast pain, sensitive nipples, gynecomastia, increased estradiol, increased testosterone, asthenia, night sweats </p>
<p><b>Rare</b> (less than 0.1%): Fever, malaise</p>
<p><b>Frequency not reported</b>: Edema</p>
<p><b>Postmarketing reports</b>: Sudden hearing loss, tinnitus, Influenza like illness<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Irritability, insomnia, mood swings, aggression,</p>
<p><b>Uncommon</b> (0.1% to 1%): Depression, emotional disorder, restlessness, increased libido, decreased libido</p>
<p><b>Frequency not reported</b>: Hostility, anxiety</p>
<p><b>Postmarketing reports</b>: Korsakoff's psychosis nonalcoholic, male orgasmic disorder, restlessness, sleep disorder<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Signs and symptoms of pulmonary microemboli may occur during or immediately after the injections and are reversible.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Sinusitis, nasopharyngitis, upper respiratory tract infection, bronchitis</p>
<p><b>Uncommon</b> (0.1% to 1%): Cough, dyspnea, snoring, dysphonia</p>
<p><b>Rare</b> (less than 0.1%): Pulmonary microembolism (POME) (cough, dyspnea, malaise, hyperhidrosis, chest pain, dizziness, paresthesia, or syncope) caused by oily solutions</p>
<p><b>Frequency not reported</b>: Sleep apnea</p>
<p><b>Postmarketing reports</b>: Chest pain, asthma, chronic obstructive pulmonary disease, hyperventilation, obstructive airway disorder, pharyngeal edema, pharyngolaryngeal pain, pulmonary embolism, respiratory distress, rhinitis, sleep apnea syndrome<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Abnormal LFT, increased AST</p>
<p><b>Rare</b> (less than 0.1%): Abnormal hepatic function</p>
<p><b>Frequency not reported</b>: Jaundice, benign liver tumor, malignant liver tumor, liver enlargement, peliosis hepatitis</p>
<p><b>Postmarketing reports</b>: ALT increased, AST increased, bilirubin increased, transaminases increased, gamma-glutamyltransferase increased<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity reactions</p>
<p><b>Frequency not reported</b>: Anaphylactic reactions</p>
<p><b>Postmarketing reports</b>: Anaphylactic shock<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Testosterone topical: Lacrimation increased</p>
<p><b>Postmarketing reports</b>: Testosterone topical: Intraocular pressure increased, vitreous detachment<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Postmarketing reports</b>: Nephrolithiasis, renal colic, renal pain<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Fortesta (testosterone)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA. </p><p id="ref_2">2. "Product Information. AndroGel (testosterone)." Unimed Pharmaceuticals, Buffalo Grove, IL. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. "Product Information. Testosterone Enanthate (testosterone)." West-Ward Pharmaceutical Corporation, Eatontown, NJ. </p><p id="ref_5">5. "Product Information. Axiron (testosterone)." Lilly, Eli and Company, Indianapolis, IN. </p><p id="ref_6">6. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_7">7. "Product Information. Testopel (testosterone)." Bartor Pharmacal Co, Inc, Rye, NY. </p><p id="ref_8">8. "Product Information. Aveed (testosterone)." Endo Pharmaceuticals Solutions Inc, Malvern, PA. </p><p id="ref_9">9. "Product Information. Testim (testosterone)." A-S Medication Solutions, Chicago, IL. </p><p id="ref_10">10. "Product Information. Androderm (testosterone topical)." SmithKline Beecham, Philadelphia, PA. </p><p id="ref_11">11. "Product Information. Depo-Testosterone (testosterone)." Pfizer U.S. Pharmaceuticals Group, New York, NY. </p><p id="ref_12">12. O'Driscoll JB, August PJ "Exacerbation of psoriasis precipitated by an oestradiol-testosterone implant." Clin Exp Dermatol 15 (1990): 68-9</p><p id="ref_13">13. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA "Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men." J Clin Endocrinol Metab 84 (1999): 3469-78</p><p id="ref_14">14. Bates GW, Cornwell CE "Iatrogenic causes of hirsutism." Clin Obstet Gynecol 34 (1991): 848-51</p><p id="ref_15">15. Fyrand O, Fiskaadal HJ, Trygstad O "Acne in pubertal boys undergoing treatment with androgens." Acta Derm Venereol 72 (1992): 148-9</p><p id="ref_16">16. Wu FC, Farley TM, Peregoudov A, Waites GM "Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organizatio Task Force on Methods for the Regulation of Male Fertility." Fertil Steril 65 (1996): 626-36</p><p id="ref_17">17. DeSanctis V, Vullo C, Urso L, Rigolin F, Cavallini A, Caramelli K, Daugherty C, Mazer N "Clinical experience using the Androderm (R) testosterone transdermal system in hypogonadal adolescents and young men with beta-thalassemia major." J Pediatr Endocrinol Metab 11 (1998): 891-900</p><p id="ref_18">18. Traupe H, von Muhlendahl KE, Bramswig J, Happle R "Acne of the fulminans type following testosterone therapy in three excessively tall boys." Arch Dermatol 124 (1988): 414-7</p><p id="ref_19">19. Bennett NJ "A burn-like lesion caused by a testosterone transdermal system." Burns 24 (1998): 478-80</p><p id="ref_20">20. Buckley DA, Wilkinson SM, Higgins EM "Contact allergy to a testosterone patch." Contact Dermatitis 39 (1998): 91-2</p><p id="ref_21">21. Matsumoto AM "Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production." J Clin Endocrinol Metab 70 (1990): 282-7</p><p id="ref_22">22. Cefalu WT, Pardridge WM, Premachandra BN "Hepatic bioavailability of thyroxine and testosterone in familial dysalbuminemic hyperthyroxinemia." J Clin Endocrinol Metab 61 (1985): 783-6</p><p id="ref_23">23. Becker U, Gluud C, Bennett P "The effect of oral testosterone on serum TBG levels in alcoholic cirrhotic men." Liver 8 (1988): 219-24</p><p id="ref_24">24. Tripathy D, Shah P, Lakshmy R, Reddy KS "Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathi hypogonadotrophic hypogonadism." Horm Metab Res 30 (1998): 642-5</p><p id="ref_25">25. Ferrera PC, Putnam DL, Verdile VP "Anabolic steroid use as the possible precipitant of dilated cardiomyopathy." Cardiology 88 (1997): 218-20</p><p id="ref_26">26. Jackson JA, Waxman J, Spiekerman AM "Prostatic complications of testosterone replacement therapy." Arch Intern Med 149 (1989): 2365-6</p><p id="ref_27">27. Wang C, Leung A, Superlano L, Steiner B, Swerdloff RS "Oligozoospermia induced by exogenous testosterone is associated with normal functioning residual spermatozoa." Fertil Steril 68 (1997): 149-53</p><p id="ref_28">28. Endres W, Shin YS, Rieth M, Block T, Schmiedt E, Knorr D "Priapism in Fabry's disease during testosterone treatment." Klin Wochenschr 65 (1987): 925</p><p id="ref_29">29. Zelissen PM, Stricker BH "Severe priapism as a complication of testosterone substitution therapy." Am J Med 85 (1988): 273-4</p><p id="ref_30">30. Parker LU, Bergfeld WF "Virilization secondary to topical testosterone." Cleve Clin J Med 58 (1991): 43-6</p><p id="ref_31">31. Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ "A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men." J Clin Endocrinol Metab 84 (1999): 3642-7</p><p id="ref_32">32. Anderson FH, Francis RM, Faulkner K "Androgen supplementation in eugonadal men with osteoporosis-effects of 6 months of treatment on bone mineral density and cardiovascula risk factors." Bone 18 (1996): 171-7</p><p id="ref_33">33. Bhasin S, Storer TW, Javanbakht M, et al. "Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels." JAMA 283 (2000): 763-70</p><p id="ref_34">34. Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ "Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men." J Clin Endocrinol Metab 79 (1994): 561-7</p><p id="ref_35">35. Lajarin F, Zaragoza R, Tovar I, Martinezhernandez P "Evolution of serum lipids in two male bodybuilders using anabolic steroids." Clin Chem 42 (1996): 970-2</p><p id="ref_36">36. Zmuda JM, Thompson PD, Dickenson R, Bausserman LL "Testosterone decreases lipoprotein(a) in men." Am J Cardiol 77 (1996): 1244</p><p id="ref_37">37. Stannard JP, Bucknell AL "Rupture of the triceps tendon associated with steroid injections." Am J Sports Med 21 (1993): 482-5</p><p id="ref_38">38. Pollard M "Tumorigenic effect of testosterone." Lancet 336 (1990): 1518</p><p id="ref_39">39. Uzych L "Anabolic-androgenic steroids and psychiatric-related effects: a review." Can J Psychiatry 37 (1992): 23-8</p><p id="ref_40">40. Nuzzo JL, Manz HJ, Maxted WC "Peliosis hepatis after long-term androgen therapy." Urology 25 (1985): 518-9</p><p id="ref_41">41. Yu MW, Chen CJ "Elevated serum testosterone levels and risk of hepatocellular carcinoma." Cancer Res 53 (1993): 790-4</p><p id="ref_42">42. Carrasco D, Prieto M, Pallardo L, Moll JL, Cruz JM, Munoz C, Berenguer J "Multiple hepatic adenomas after long-term therapy with testosterone enanthate. Review of the literature." J Hepatol 1 (1985): 573-8</p><p id="ref_43">43. Falk H, Thomas LB, Popper H, Ishak KG "Hepatic angiosarcoma associated with androgenic-anabolic steroids." Lancet 2 (1979): 1120-3</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What are the brands of testosterone?</li>
<li>How much does Jatenzo cost?</li>
<li>Is Xyosted a controlled substance?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about testosterone</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Support Group</li>
<li>Pricing &amp; Coupons</li>
<li>479 Reviews</li>
<li>Drug class: androgens and anabolic steroids</li>
<li>FDA Alerts (6)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Testosterone implant</li>
<li>Testosterone injection</li>
<li>Testosterone nasal</li>
<li>Testosterone oral</li>
<li data-more-config-id="list-data-resources-consumer">... +6 more</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>AndroGel, Xyosted, Depo-Testosterone, Androderm, ... +12 more</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +6 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Hypogonadism, Male</li>
<li>Gender Dysphoria</li>
<li>Klinefelter Syndrome</li>
<li>Breast Cancer, Palliative</li>
<li>Delayed Puberty, Male</li>
<li>Postpartum Breast Pain</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to testosterone: buccal film extended release, compounding powder, intramuscular solution, nasal gel, oral capsule, subcutaneous implant, subcutaneous solution, transdermal cream, transdermal film extended release, transdermal gel, transdermal ointment, transdermal solution</i></p><h3>General</h3><p>The most frequently reported side effects with this drug are edema, acne, site pain, injection site erythema, cough or dyspnea during or immediately after injection.</p><p></p><p>The most frequently reported side effects with testosterone topical are skin reaction (16.1%) and allergic contact dermatitis (up to 37%).<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Testosterone topical: Skin reaction (16.1%), burn-like blisters (12%), itching, allergic contact dermatitis (up to 37%)</p><p><b>Common</b> (1% to 10%): Acne, induration, burning</p><p><b>Uncommon</b> (0.1% to 1%): Alopecia, erythema, rash (including rash popular), pruritus, dry skin, folliculitis (testosterone topical)</p><p><b>Frequency not reported</b>: Seborrhea, urticaria, male pattern baldness, hirsutism injection site inflammation</p><p><b>Postmarketing reports</b>: Angioedema, angioneurotic edema, hyperhidrosis, discolored hair, leukocytoclastic vasculitis<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Very common</b> (10% or more): Accelerated growth</p><p><b>Common</b> (1% to 10%): Increased estradiol, hypogonadism</p><p><b>Uncommon</b> (0.1% to 1%): Increased blood testosterone</p><p><b>Frequency not reported</b>: Signs of virilization in women (e.g., hoarseness, acne, hirsutism, menstrual irregularity, clitoral enlargement, and alopecia), precocious puberty (in prepubertal males)</p><p><b>Postmarketing reports</b>: Hyperparathyroidism, prolactin increased, testosterone increased<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Testosterone buccal film: Gingivitis (32.6%)</p><p><b>Common</b> (1% to 10%): Diarrhea, oily stools (due to IM injection oily solvent); Testosterone topical: Gastroesophageal reflux disease, gastrointestinal bleeding, gum or mouth irritation (9.2%), taste bitter, gum pain, gum tenderness, gum edema, taste perversion</p><p><b>Uncommon</b> (0.1% to 1%): Nausea</p><p><b>Rare</b> (less than 0.1%): Abdominal pain</p><p><b>Frequency not reported</b>: Abdominal disorder, intraabdominal hemorrhage</p><p><b>Postmarketing reports</b>: Vomiting; Testosterone buccal film: Dry mouth, gingival swelling, lip swelling, mouth ulceration, stomatitis<sup>[Ref]</sup></p><p>The majority of gum-related adverse events were transient.<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Testosterone topical: Application site pruritus (up to 37%), application site blistering (12%)</p><p><b>Common</b> (1% to 10%): Injection site pain, injection site discomfort, injection site pruritus, erythema, injection site hematoma, injection site irritation, injection site inflammation; injection site reaction; Topical testosterone: Application site erythema, application site warmth, application site irritation, application site vesicles, application site exfoliation, application site burning, application site induration, bullae at application site, mechanical irritation at application site, rash at application site, contamination of application site</p><p><b>Postmarketing reports</b>: Injection site abscess, procedural pain, application site swelling (topical testosterone)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hot flush, hypertension</p><p><b>Uncommon</b> (0.1% to 1%): Cardiovascular disorder</p><p><b>Frequency not reported</b>: Venous thromboembolism</p><p><b>Postmarketing reports</b>: Angina pectoris, cardiac arrest, cardiac failure, coronary artery disease, coronary artery occlusion, myocardial infarction, tachycardia, cerebral infarction, cerebrovascular accident, circulatory collapse, deep venous thrombosis, syncope, thromboembolism, thrombosis, venous insufficiency, stroke<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Abnormal prostate examination, benign prostate hyperplasia (BPH), ejaculation disorder, prostatitis</p><p><b>Uncommon</b> (0.1% to 1%): Prostate induration, prostatic disorder, testicular pain, decreased urine flow, urinary retention, urinary tract disorder, nocturia, dysuria</p><p><b>Rare</b> (less than 0.1%): Micturition disorders, epididymitis, bladder irritability, impotence, inhibition of testicular function and testicular atrophy</p><p><b>Frequency not reported</b>: Oligospermia, priapism, benign prostatic hyperplasia (prostatic growth to eugonadal state), excessive frequency and duration of erections; Pediatrics: Precocious sexual development, an increased frequency of erections, phallic enlargement</p><p><b>Postmarketing reports</b>: Prostate infection, calculus urinary, dysuria, hematuria, urinary tract disorder, pollakiuria, azoospermia<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Polycythemia, hematocrit increased</p><p><b>Uncommon</b> (0.1% to 1%): Increased red blood cell count, increased hemoglobin, prolonged activated partial thromboplastin time, prolonged prothrombin time</p><p><b>Frequency not reported</b>: Blood and lymphatic system disorders, suppression of clotting factors II, V, VII, and X, bleeding in patients on concomitant anticoagulant therapy</p><p><b>Postmarketing reports</b>: Thrombocytopenia, anemia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Weight increased, appetite increased, fluid retention (sodium, chloride, water, potassium, calcium, and inorganic phosphates)</p><p><b>Uncommon</b> (0.1% to 1%): Increased glycosylated hemoglobin, hypercholesterolemia, increased triglyceride</p><p><b>Frequency not reported</b>: Abnormal lipids (decrease in serum LDL, HDL, and triglycerides), metabolism and nutrition disorders, hypercalcemia</p><p><b>Postmarketing reports</b>: Hypoglycemia, diabetes mellitus, fluid retention, hyperlipidemia, hypertriglyceridemia, blood glucose increased<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, hemarthrosis (testosterone topical)</p><p><b>Uncommon</b> (0.1% to 1%): Arthralgia, pain in extremity, muscle spasm, muscle strain, myalgia, musculoskeletal stiffness, increased creatine phosphokinase</p><p><b>Frequency not reported</b>: Pediatrics: Premature epiphyseal closure, increased bone formation</p><p><b>Postmarketing reports</b>: Musculoskeletal chest pain, musculoskeletal pain, myalgia, osteopenia, osteoporosis, systemic lupus erythematosus<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, vertigo (topical testosterone)</p><p><b>Uncommon</b> (0.1% to 1%): Migraine, tremor, dizziness</p><p><b>Frequency not reported</b>: Nervousness, paresthesia</p><p><b>Postmarketing reports</b>: Cerebrovascular insufficiency, reversible ischemic neurological deficiency, transient ischemic attack, amnesia<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Prostatic specific antigen (PSA) increased, prostate cancer</p><p><b>Uncommon</b> (0.1% to 1%): Prostatic intraepithelial neoplasia</p><p><b>Rare</b> (less than 0.1%): Neoplasms benign, malignant, and unspecified (including cysts and polyps)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue, hyperhidrosis; chills, body pain, smell disorder</p><p><b>Uncommon</b> (0.1% to 1%): Breast induration, breast pain, sensitive nipples, gynecomastia, increased estradiol, increased testosterone, asthenia, night sweats </p><p><b>Rare</b> (less than 0.1%): Fever, malaise</p><p><b>Frequency not reported</b>: Edema</p><p><b>Postmarketing reports</b>: Sudden hearing loss, tinnitus, Influenza like illness<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Irritability, insomnia, mood swings, aggression,</p><p><b>Uncommon</b> (0.1% to 1%): Depression, emotional disorder, restlessness, increased libido, decreased libido</p><p><b>Frequency not reported</b>: Hostility, anxiety</p><p><b>Postmarketing reports</b>: Korsakoff's psychosis nonalcoholic, male orgasmic disorder, restlessness, sleep disorder<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Signs and symptoms of pulmonary microemboli may occur during or immediately after the injections and are reversible.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Sinusitis, nasopharyngitis, upper respiratory tract infection, bronchitis</p><p><b>Uncommon</b> (0.1% to 1%): Cough, dyspnea, snoring, dysphonia</p><p><b>Rare</b> (less than 0.1%): Pulmonary microembolism (POME) (cough, dyspnea, malaise, hyperhidrosis, chest pain, dizziness, paresthesia, or syncope) caused by oily solutions</p><p><b>Frequency not reported</b>: Sleep apnea</p><p><b>Postmarketing reports</b>: Chest pain, asthma, chronic obstructive pulmonary disease, hyperventilation, obstructive airway disorder, pharyngeal edema, pharyngolaryngeal pain, pulmonary embolism, respiratory distress, rhinitis, sleep apnea syndrome<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Abnormal LFT, increased AST</p><p><b>Rare</b> (less than 0.1%): Abnormal hepatic function</p><p><b>Frequency not reported</b>: Jaundice, benign liver tumor, malignant liver tumor, liver enlargement, peliosis hepatitis</p><p><b>Postmarketing reports</b>: ALT increased, AST increased, bilirubin increased, transaminases increased, gamma-glutamyltransferase increased<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity reactions</p><p><b>Frequency not reported</b>: Anaphylactic reactions</p><p><b>Postmarketing reports</b>: Anaphylactic shock<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Testosterone topical: Lacrimation increased</p><p><b>Postmarketing reports</b>: Testosterone topical: Intraocular pressure increased, vitreous detachment<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Postmarketing reports</b>: Nephrolithiasis, renal colic, renal pain<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Fortesta (testosterone)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA. </p><p id="ref_2">2. "Product Information. AndroGel (testosterone)." Unimed Pharmaceuticals, Buffalo Grove, IL. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. "Product Information. Testosterone Enanthate (testosterone)." West-Ward Pharmaceutical Corporation, Eatontown, NJ. </p><p id="ref_5">5. "Product Information. Axiron (testosterone)." Lilly, Eli and Company, Indianapolis, IN. </p><p id="ref_6">6. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_7">7. "Product Information. Testopel (testosterone)." Bartor Pharmacal Co, Inc, Rye, NY. </p><p id="ref_8">8. "Product Information. Aveed (testosterone)." Endo Pharmaceuticals Solutions Inc, Malvern, PA. </p><p id="ref_9">9. "Product Information. Testim (testosterone)." A-S Medication Solutions, Chicago, IL. </p><p id="ref_10">10. "Product Information. Androderm (testosterone topical)." SmithKline Beecham, Philadelphia, PA. </p><p id="ref_11">11. "Product Information. Depo-Testosterone (testosterone)." Pfizer U.S. Pharmaceuticals Group, New York, NY. </p><p id="ref_12">12. O'Driscoll JB, August PJ "Exacerbation of psoriasis precipitated by an oestradiol-testosterone implant." Clin Exp Dermatol 15 (1990): 68-9</p><p id="ref_13">13. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA "Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men." J Clin Endocrinol Metab 84 (1999): 3469-78</p><p id="ref_14">14. Bates GW, Cornwell CE "Iatrogenic causes of hirsutism." Clin Obstet Gynecol 34 (1991): 848-51</p><p id="ref_15">15. Fyrand O, Fiskaadal HJ, Trygstad O "Acne in pubertal boys undergoing treatment with androgens." Acta Derm Venereol 72 (1992): 148-9</p><p id="ref_16">16. Wu FC, Farley TM, Peregoudov A, Waites GM "Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organizatio Task Force on Methods for the Regulation of Male Fertility." Fertil Steril 65 (1996): 626-36</p><p id="ref_17">17. DeSanctis V, Vullo C, Urso L, Rigolin F, Cavallini A, Caramelli K, Daugherty C, Mazer N "Clinical experience using the Androderm (R) testosterone transdermal system in hypogonadal adolescents and young men with beta-thalassemia major." J Pediatr Endocrinol Metab 11 (1998): 891-900</p><p id="ref_18">18. Traupe H, von Muhlendahl KE, Bramswig J, Happle R "Acne of the fulminans type following testosterone therapy in three excessively tall boys." Arch Dermatol 124 (1988): 414-7</p><p id="ref_19">19. Bennett NJ "A burn-like lesion caused by a testosterone transdermal system." Burns 24 (1998): 478-80</p><p id="ref_20">20. Buckley DA, Wilkinson SM, Higgins EM "Contact allergy to a testosterone patch." Contact Dermatitis 39 (1998): 91-2</p><p id="ref_21">21. Matsumoto AM "Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production." J Clin Endocrinol Metab 70 (1990): 282-7</p><p id="ref_22">22. Cefalu WT, Pardridge WM, Premachandra BN "Hepatic bioavailability of thyroxine and testosterone in familial dysalbuminemic hyperthyroxinemia." J Clin Endocrinol Metab 61 (1985): 783-6</p><p id="ref_23">23. Becker U, Gluud C, Bennett P "The effect of oral testosterone on serum TBG levels in alcoholic cirrhotic men." Liver 8 (1988): 219-24</p><p id="ref_24">24. Tripathy D, Shah P, Lakshmy R, Reddy KS "Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathi hypogonadotrophic hypogonadism." Horm Metab Res 30 (1998): 642-5</p><p id="ref_25">25. Ferrera PC, Putnam DL, Verdile VP "Anabolic steroid use as the possible precipitant of dilated cardiomyopathy." Cardiology 88 (1997): 218-20</p><p id="ref_26">26. Jackson JA, Waxman J, Spiekerman AM "Prostatic complications of testosterone replacement therapy." Arch Intern Med 149 (1989): 2365-6</p><p id="ref_27">27. Wang C, Leung A, Superlano L, Steiner B, Swerdloff RS "Oligozoospermia induced by exogenous testosterone is associated with normal functioning residual spermatozoa." Fertil Steril 68 (1997): 149-53</p><p id="ref_28">28. Endres W, Shin YS, Rieth M, Block T, Schmiedt E, Knorr D "Priapism in Fabry's disease during testosterone treatment." Klin Wochenschr 65 (1987): 925</p><p id="ref_29">29. Zelissen PM, Stricker BH "Severe priapism as a complication of testosterone substitution therapy." Am J Med 85 (1988): 273-4</p><p id="ref_30">30. Parker LU, Bergfeld WF "Virilization secondary to topical testosterone." Cleve Clin J Med 58 (1991): 43-6</p><p id="ref_31">31. Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ "A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men." J Clin Endocrinol Metab 84 (1999): 3642-7</p><p id="ref_32">32. Anderson FH, Francis RM, Faulkner K "Androgen supplementation in eugonadal men with osteoporosis-effects of 6 months of treatment on bone mineral density and cardiovascula risk factors." Bone 18 (1996): 171-7</p><p id="ref_33">33. Bhasin S, Storer TW, Javanbakht M, et al. "Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels." JAMA 283 (2000): 763-70</p><p id="ref_34">34. Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ "Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men." J Clin Endocrinol Metab 79 (1994): 561-7</p><p id="ref_35">35. Lajarin F, Zaragoza R, Tovar I, Martinezhernandez P "Evolution of serum lipids in two male bodybuilders using anabolic steroids." Clin Chem 42 (1996): 970-2</p><p id="ref_36">36. Zmuda JM, Thompson PD, Dickenson R, Bausserman LL "Testosterone decreases lipoprotein(a) in men." Am J Cardiol 77 (1996): 1244</p><p id="ref_37">37. Stannard JP, Bucknell AL "Rupture of the triceps tendon associated with steroid injections." Am J Sports Med 21 (1993): 482-5</p><p id="ref_38">38. Pollard M "Tumorigenic effect of testosterone." Lancet 336 (1990): 1518</p><p id="ref_39">39. Uzych L "Anabolic-androgenic steroids and psychiatric-related effects: a review." Can J Psychiatry 37 (1992): 23-8</p><p id="ref_40">40. Nuzzo JL, Manz HJ, Maxted WC "Peliosis hepatis after long-term androgen therapy." Urology 25 (1985): 518-9</p><p id="ref_41">41. Yu MW, Chen CJ "Elevated serum testosterone levels and risk of hepatocellular carcinoma." Cancer Res 53 (1993): 790-4</p><p id="ref_42">42. Carrasco D, Prieto M, Pallardo L, Moll JL, Cruz JM, Munoz C, Berenguer J "Multiple hepatic adenomas after long-term therapy with testosterone enanthate. Review of the literature." J Hepatol 1 (1985): 573-8</p><p id="ref_43">43. Falk H, Thomas LB, Popper H, Ishak KG "Hepatic angiosarcoma associated with androgenic-anabolic steroids." Lancet 2 (1979): 1120-3</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What are the brands of testosterone?</li>
<li>How much does Jatenzo cost?</li>
<li>Is Xyosted a controlled substance?</li>
</ul><h2>More about testosterone</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Support Group</li>
<li>Pricing &amp; Coupons</li>
<li>479 Reviews</li>
<li>Drug class: androgens and anabolic steroids</li>
<li>FDA Alerts (6)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Testosterone implant</li>
<li>Testosterone injection</li>
<li>Testosterone nasal</li>
<li>Testosterone oral</li>
<li data-more-config-id="list-data-resources-consumer">... +6 more</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +6 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Hypogonadism, Male</li>
<li>Gender Dysphoria</li>
<li>Klinefelter Syndrome</li>
<li>Breast Cancer, Palliative</li>
<li>Delayed Puberty, Male</li>
<li>Postpartum Breast Pain</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>